Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

Archives of General Psychiatry
N C AndreasenD S O'Leary

Abstract

The "hypofrontality hypothesis" has been supported by many neuroimaging studies, but not all, perhaps because of heterogeneity of samples. The present study examined three different samples that permitted assessment of a variety of confounders, such as effects of long-term treatment, chronicity of illness, and presenting phenomenology: (1) 13 neuroleptic-naive schizophrenic patients, (2) 23 nonnaive schizophrenic patients who had been relatively chronically ill but were medication free for at least 3 weeks, and (3) 15 healthy normal volunteers. Regional cerebral blood flow was measured using single-photon emission computed tomography with xenon 133 as the tracer. The control condition consisted of looking at undulating colored shapes on a video monitor, while the experimental task was the Tower of London. We observed the Tower of London to be a relatively specific stimulant of the left mesial frontal cortex (probably including parts of the cingulate gyrus) in healthy normal volunteers. Both the neuroleptic-naive and the nonnaive patients lacked this area of activation, as well as a related one in the right parietal cortex (representing the circuitry specifically activated by the Tower of London). Decreased activation occurred o...Continue Reading

References

Jul 5, 2013·Indian Journal of Psychiatry·Hossein HaghirMahla Radmard
Jun 3, 1995·Lancet·R C Gur, R E Gur
Jun 1, 1996·Neuropsychologia·S C BakerT W Robbins
Apr 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·K P EbmeierG M Goodwin
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·N C AndreasenR D Hichwa
Aug 31, 1999·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·C H Fu, P K McGuire
May 10, 2001·Schizophrenia Research·M E ShentonR W McCarley
Sep 27, 2005·Brain : a Journal of Neurology·Garry D HoneyPaul C Fletcher
Oct 31, 2006·BMC Psychiatry·Liezl KoenEsme Jordaan
Nov 13, 2008·Nature Reviews. Neuroscience·Tomás PausJay N Giedd
Aug 21, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel Paul Eisenberg, Karen Faith Berman
Nov 26, 2009·Schizophrenia Bulletin·Chiara SpironelliLuciano Stegagno
Sep 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tyler A LeshCameron S Carter
May 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F BiverF Lotstra
Jun 5, 2010·Cerebral Cortex·Christoph P KallerJosef M Unterrainer
Oct 1, 1994·Progress in Neurobiology·R M Ridley
May 13, 1999·Psychiatry Research·P R SzeszkoJ A Lieberman
May 1, 1995·Psychological Medicine·T J CrawfordL Henderson
Dec 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·B S Peterson
Dec 13, 2006·Development and Psychopathology·Angus W MacDonald, Matthew V Chafee
May 17, 2005·Psychiatry Research·Benedikt ReuterNorbert Kathmanna
Dec 4, 1998·Biological Psychiatry·J A LiebermanJ E Kraus
Jul 8, 1999·Biological Psychiatry·D MalaspinaR Van Heertum
Jun 1, 1993·Biological Psychiatry·W H Wilson, R J Mathew

Related Concepts

Antipsychotic Effect
Cerebral Blood Flow Imaging
Xenon Radioisotopes
Central Nervous System Stimulant [EPC]
Adrenal Cortex Diseases
Central Nervous System Stimulants
Tomography, Emission-Computed, Single-Photon
Schizophrenia
Chronic Disease
Memory for Designs Test

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here